Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00826930
Other study ID # DP100-201
Secondary ID
Status Terminated
Phase Phase 1
First received January 21, 2009
Last updated August 11, 2010
Start date March 2009
Est. completion date May 2009

Study information

Verified date August 2010
Source Diffusion Pharmaceuticals LLC
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the impact of Trans Sodium Crocetinate (TSC) on oxygen levels in brain tumor tissue in patients with high grade glioma. The proposed clinical indication for TSC is a radiation sensitizer for the treatment of cancerous tumors.


Description:

In this open-label, one-site study, up to 48 patients with high grade glioma (HGG) who are undergoing biopsy or partial debulking of the tumor as part of standard of care will have an oxygen monitoring probe placed in residual tumor tissue. Oxygen levels in the tumor tissue will be measured prior to and after administering a single bolus injection of TSC. Safety assessments will occur throughout the trial, including at a 7 to 14 day follow-up visit. Pharmacokinetic assessments will be performed prior to and during the first 24 hours after TSC dosing.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date May 2009
Est. primary completion date May 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- At least 18 years old.

- Prior histological diagnosis of high grade glioma (HGG) with prior initial treatment and radiation therapy for HGG; recurrence of HGG suspected, and care plan includes surgical procedure.

- Undergoing surgical procedure for clinical reasons, and gross surgical resection not expected.

- Neurosurgeon is planning stereotactic biopsy or tumor debulking for clinical reasons; frozen tissue confirmation of malignancy during this operative procedure is necessary.

- Neurosurgeon evaluates that placement of oxygen monitoring probe after biopsy or debulking can be done safely without complications.

- Contrast enhancing disease on MRI within 21 days prior to enrollment.

- Karnofsky Performance Score = 60 at Screening.

- Recovered from toxicity of prior antineoplastic therapy, and off cytotoxic chemotherapy for 7 days prior to Screening.

- Recovered from prior radiotherapy and had at least 21 days elapse since completion of radiotherapy prior to Screening.

- Recovered from prior surgery for their brain tumor in investigator's clinical judgment.

- If female, negative serum or urine pregnancy test at Screening.

- Within 2 weeks of starting study, hematologic and renal functions as specified: Absolute neutrophil count = 1500/mm3, platelets = 100,000/mm3, hemoglobin = 9.0g/dL, creatinine = 1.7mg/dl, serum bilirubin = 1.5mg/dL, blood urea nitrogen within 2 times the upper limit of normal, transaminases = 4 times above the upper limits of the institutional norm, and prothrombin time and partial thromboplastin time within institutional norm or below.

- Patient or patient's medical power of attorney provided written consent to participate in the study.

- Mini Mental Status Exam score = 15.

Exclusion Criteria:

- Pregnant or lactating.

- Receiving concurrent cytotoxic chemotherapy for their tumor within 7 days prior to Screening, or decision is made at the time of surgery to treat with other modality of treatment (e.g., gliadel wafers).

- Serious concurrent infection or medical illness which would jeopardize the ability of the patient to safely participate.

- Behavioral, cognitive, or psychiatric disease or personal situation that might interfere with optimal participation.

- Cannot undergo an MRI.

- Received an investigational drug not approved for human use by the FDA within 30 days of enrollment.

- Previously received TSC.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Drug:
Trans Sodium Crocetinate (TSC)
Single bolus intravenous administration in a superficial vein of the arm over a period of up to 2 minutes.

Locations

Country Name City State
United States Johns Hopkins Medical Institute/Johns Hopkins Hospital Baltimore Maryland

Sponsors (1)

Lead Sponsor Collaborator
Diffusion Pharmaceuticals LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in tumor tissue oxygen monitoring recordings Daily while inpatient No
Primary Safety assessments (laboratory tests) Daily while inpatient, 7-14 Day Follow-up No
Secondary Pharmacokinetic assessments Day 1, Day 2 No
Secondary Tumor hypoxia biomarkers (HIF 1-alpha, osteopontin, carbonic anhydrase IX) Daily while inpatient No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05023551 - Study of DSP-0390 in Patients With Recurrent High-Grade Glioma Early Phase 1
Terminated NCT01902771 - Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors Phase 1
Active, not recruiting NCT02655601 - Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 Phase 2
Terminated NCT03690869 - REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma Phase 1/Phase 2
Completed NCT01466686 - Low Dose Radiation Therapy for Glioblastoma Multiforme Phase 2
Recruiting NCT05925218 - Circulating Tumor DNA Collection From Patients With High Grade Gliomas
Recruiting NCT05212272 - MRI in High-Grade Glioma Patients Undergoing Chemoradiation
Active, not recruiting NCT04911621 - Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma Phase 1/Phase 2
Not yet recruiting NCT06333899 - Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion Early Phase 1
Recruiting NCT04734444 - SonoClear Acoustic Coupling Fluid (ACF) Mimicking Brain Tissue N/A
Completed NCT03775369 - Glioma and Exercising N/A
Completed NCT02022644 - Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma Phase 1
Completed NCT00780819 - Borderzone Sampling N/A
Recruiting NCT06072586 - Study of BDTX-1535 in Recurrent High-Grade Glioma (HGG) Participants With EGFR Alterations or Fusions Early Phase 1
Completed NCT01390948 - A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma Phase 2
Recruiting NCT03952598 - Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy N/A
Recruiting NCT05630664 - Liquid Biopsy in High-grade Gliomas and Meningiomas
Recruiting NCT05298995 - GD2-CAR T Cells for Pediatric Brain Tumours Phase 1
Completed NCT01222754 - Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas Phase 1
Recruiting NCT05278208 - Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors Phase 1/Phase 2